Compare Eli Lilly And Co (LLY) vs Ferrari NV (RACE) Price & Performance

Eli Lilly (LLY) trades at $1,221.21, down 0.84% today, but maintains strong bullish momentum with consistent earnings beats and robust revenue growth. The stock shows technical strength with bullish moving averages and support at $1,207, while fundamentals reveal exceptional profitability with 33.53% net margins and 48% revenue growth in Q2 2026. Recent news highlights the company's aggressive protection of its obesity drug pipeline against black market sales.

LLY presents a compelling growth story with dominant market positioning in weight-loss drugs and strong analyst support (73% buy ratings). Key risks include regulatory scrutiny and competitive pressures, but the company's raised guidance and pipeline advancements support continued upside toward the $1,380 consensus target.

Ferrari (RACE) trades at $405.73, down 0.26% on the day, with a bullish technical signal from moving averages and strong fundamental performance. The company reported Q2 2026 EPS of $2.99, beating estimates of $2.83, and raised full-year guidance, driven by robust personalization demand and pricing power. Revenue growth has been consistent, reaching $7.15B in 2025, with a net income margin of 22.25% and high profitability metrics like a 45.45% ROE.

The outlook remains positive given strong order books, margin expansion, and analyst consensus favoring a buy rating with a $462.67 price target. Key risks include premium valuation multiples limiting upside and sensitivity to luxury demand cycles. The stock's proximity to its 52-week high suggests momentum but warrants caution on overextension.